Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

49.60 +0.51 (+1.04%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Sanofi's Oral Treatment For Sleeping Sickness Gets FDA Approval
The FDA has approved Sanofi SA's (NASDAQ: SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of... 
Via Benzinga
Exposures Product Safety
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage... 
Via Benzinga
Exposures COVID-19
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
Exposures COVID-19
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
Sanofi Invests To Build Internal Capabilities in mRNA
Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will ... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
Sanofi Divests 16 Consumer Health Brands To Stada
Amid a reorganization scheme aimed at slashing costs and prioritizing blockbuster immunology Dupixent, Sanofi SA (NASDAQ: SNY) will offload 16 consumer health... 
Via Benzinga
Sanofi's Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin
Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
AstraZeneca's Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV
AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV). The trial... 
Via Benzinga
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two... 
Via Benzinga
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial
Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
How This Pharma Company Can Benefit From Its Competitors
Delays in FDA approval for Incyte could spell good news for Sanofi. 
Via The Motley Fool
Exposures Product Safety
Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis
The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with... 
Via Benzinga
BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial
BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates the therapeutic cancer... 
Via Benzinga
Sanofi Scores FDA Approval For Flu-Shot Facility In US
The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production of its... 
Via Benzinga
Exposures Product Safety
Elanco Is Looking To Challenge Zoetis, Will The $440 Million Kindred Buyout Help?
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring. 
Via Investor's Business Daily
Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection
Sanofi SA’s (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This... 
Via Benzinga
Exposures Product Safety
Elevation Oncology Files for $100M IPO
Elevation Oncology has filed to raise $100 million in an IPO. See SEC prospectus here. Proceeds will be used to support the development of seribantumab that failed... 
Via Benzinga
Topics Initial Public Offering Regulatory Compliance
Exposures Legal Regulatory Securities Market
Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy
Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast... 
Via Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
P/E Ratio Insights for Sanofi
In the current market session, Sanofi Inc. (NASDAQ:SNY) is trading at $52.60, after a 1.55% decrease. However, over the past month, the stock spiked by 4.32%, and in... 
Via Benzinga
Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder
Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of... 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.